Phaseline

Targets › PIK3R2

PIK3R2 (Phosphatidylinositol 3-kinase regulatory subunit beta): drug programs, companies and trials

2 programs from 2 companies in 9 trials: 5 Phase 2, 4 Phase 1; Oncology, Other; next expected readout Feb 2027.

Regulatory subunit of phosphoinositide-3-kinase (PI3K), a kinase that phosphorylates PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. (UniProt, O00459)

Open in Phaseline: the race on PIK3R2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Cancer Institute (NCI)Taselisib (GDC-0032)
PI3-kinase class I inhibitor
PIK3R1, PIK3CB, PIK3CG, PIK3CA, PIK3R2Phase 2Advanced LymphomaMar 2027
SovargenPaxalisib (SVG103)
PI3-kinase class I inhibitor
PIK3R1, PIK3CB, PIK3CG, PIK3CA, PIK3R2Phase 1Focal Cortical Dysplasia; Primary Central Nervous System Lymphoma; Glioblastoma; CDK Gene Mutation …Feb 2027

Conditions

Advanced Lymphoma (1) Focal Cortical Dysplasia (1) Primary Central Nervous System Lymphoma (1) Glioblastoma (1) CDK Gene Mutation (1) Recurrent Atypical Teratoid/Rhabdoid Tumor (1) Brain Metastases (1) Malignant Primary Gliomas (1) Childhood Cancer (1)

Modalities

small molecule (2)

Companies

National Cancer Institute (NCI) (1) Sovargen (1)

Related targets

PIK3R1 (2) PIK3CB (2) PIK3CG (2) PIK3CA (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.